1,721,154 research outputs found
Pharmacological therapies for Liposarcoma
No full textLiposarcoma (LS) is one of the most common adult soft tissue sarcomas (STS). For metastatic disease, systemic treatment options were historically represented by standard cytotoxic chemotherapy. More recently, innovative therapies have been introduced and they are currently part of the therapeutic armamentarium, positively impacting disease control and patients' quality of life. Moreover, in the last decade, a better understanding of the molecular characteristics of each STS subtype allowed to detect new potential targets and develop novel, biology-driven compounds at different stages of testing. Areas covered: This review is focused on LS, retracing their pharmacological management, starting with a summary of results achieved with standard chemotherapy, then moving to a deeper analysis on data obtained with new, approved therapies and finally reporting an update on ongoing clinical trials, thus providing an overview on the current scenario and outlining how it might evolve in the coming years. Expert Commentary: Important strides have been made in the knowledge and treatment of LS. Peculiar molecular features and fundamental signalling pathways represent nowadays druggable targets for novel therapies. However, predictive biomarkers still need to be identified in order to better select the target population, to possibly test combinations of drugs, with the ultimate goal of improving outcomes
The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma
Full text linkABSTRACT: The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the ‘place’ of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management
Neoadjuvant chemotherapy in soft tissue sarcomas: Latest evidence and clinical implications
No full textSoft tissue sarcomas are a rare and multifaceted group of solid tumours. Neoadjuvant chemotherapy is increasingly used to limit loss of function after wide surgical excision with the ultimate aim of improving patient survival. Recently, advances in the identification of effective treatment strategies and improvements in patient risk stratification have been reached. A randomized trial demonstrated that neoadjuvant epirubicin and ifosfamide improves survival of patients affected by five high-risk soft tissue sarcoma histologies of trunk and extremities, including undifferentiated pleomorphic sarcoma, myxoid liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumours, and leiomyosarcoma. Selection of patients for these treatments is expected to be improved by the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system, as it tailors T-stage categories on primary tumour site and considers a prognostic nomogram for retroperitoneal sarcoma, which also includes soft tissue sarcoma histology and other patient and tumour features not directly included in the TNM staging. Within this framework, this article will present neoadjuvant treatment strategies for high-risk soft tissue sarcoma, emphasizing the most recent advances and discussing the need for further research to improve the effectiveness of neoadjuvant treatments
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib
No full textThe rectum is a rare site of gastrointestinal stromal tumor (GIST), and factors determining long-term outcome remain unclear. In a population study, we assessed the outcome of rectal GIST patients treated at two referral centers
First- and second-line systemic treatments for metastatic and locally advanced soft tissue sarcomas in adults
No full textThis is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of systemic therapy for the treatment of metastatic soft tissue sarcomas in a first-line metastatic setting. To assess the effects of systemic therapy for the treatment of metastatic soft tissue sarcomas in a second-line metastatic setting. To assess the effects of chemotherapy regimens adapted to specific sarcoma histologies. © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
